R-ESHAP联合聚乙二醇化重组人粒细胞刺激因子作为复发/难治性弥漫性大B细胞淋巴瘤患者自体干细胞移植的有效外周血干细胞动员方案。

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.

作者信息

Montoro Juan, Andreola Giovanna, Gardellini Angelo, Babic Aleksandra, Negri Mara, Frungillo Niccolò, Martinelli Giovanni, Laszlo Daniele

机构信息

Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

出版信息

Transfus Apher Sci. 2014 Jun;50(3):411-4. doi: 10.1016/j.transci.2014.03.006. Epub 2014 Apr 4.

DOI:10.1016/j.transci.2014.03.006

PMID:24751603

Abstract

Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma. We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ⩾ 2 × 10(6) CD34+cells/kg, 80% of them at least 5 × 10(6) CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.

摘要

干细胞（SC）动员受淋巴瘤患者动员方案的显著影响。我们评估了30例接受SC动员的复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）患者的数据。所有患者均接受R-ESHAP方案加单剂量培非格司亭。所有患者均采集到≥2×10⁶个CD34⁺细胞/kg，其中80%的患者采集到至少5×10⁶个CD34⁺细胞/kg。该方案的不良反应包括骨髓抑制和中性粒细胞减少性发热。在此，我们的结果表明，R-ESHAP方案加培非格司亭是DLBCL患者的一种高效动员策略，且不良事件发生率较低。